We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in Store for Innoviva (INVA) This Earnings Season?
Read MoreHide Full Article
We expect royalties from Innoviva, Inc.’s (INVA - Free Report) collaborated drugs to have driven revenues in fourth-quarter 2019.
Shares of the company have lost 12.4% in the past year.
Innoviva’s earnings performance has been dismal over the trailing four quarters. The company missed expectations in three of the last four quarters. The trailing four-quarter negative earnings surprise is 15.82%, on average.
In the last reported quarter, Innoviva delivered a negative earnings surprise of 10.0%.
Let’s see how things are shaping up prior to this announcement.
Factors at Play
Innoviva has a long-acting beta2 agonist (“LABA”) collaboration agreement with British pharma giant, Glaxo (GSK - Free Report) , which is the sole revenue source for the former. Under this agreement, Innoviva records royalties on global sales of certain Glaxo’s Ellipta products — Relvar/Breo, Anoro and Trelegy. Demand for these respiratory drugs is likely to have driven revenues for the company.
Trelegy Ellipta, the most recent among these, has demonstrated a strong growth trend in the first nine months of 2019. We expect strong demand for the drug to have continued in the fourth quarter, driving sales.
Moreover, U.S. sales of Anoro Ellipta returned to growth and ex-U.S. sales were strong in the third quarter. The sales-growth trend is likely to have continued in the soon-to-be reported quarter.
However, the U.S. generic launch of Glaxo’s respiratory drug, Advair, in early 2019 negatively impacted pricing for Relvar/Breo Ellipta in the United States. We expect U.S. sales to have declined in the quarter. Meanwhile, share gains in certain European markets and growth in Japan are likely to have driven sales in ex-U.S. markets for Relvar/Breo Ellipta.
We expect foreign currency translation to have positively impacted ex-U.S. sales of these drugs, thus driving royalties for Innoviva.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Innoviva this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Earnings ESP: Innoviva’s Earnings ESP is 0.00%. This is because both the Most Accurate Estimate and the Zacks Consensus Estimate stand at earnings of 60 cents.
Zacks Rank: Innoviva currently carries a Zacks Rank #3.
Here are some biotech stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat in their upcoming releases.
Horizon Pharma has an Earnings ESP of +1.85% and a Zacks Rank #3.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.7% per year. So be sure to give these hand-picked 7 your immediate attention.
Image: Bigstock
What's in Store for Innoviva (INVA) This Earnings Season?
We expect royalties from Innoviva, Inc.’s (INVA - Free Report) collaborated drugs to have driven revenues in fourth-quarter 2019.
Shares of the company have lost 12.4% in the past year.
Innoviva’s earnings performance has been dismal over the trailing four quarters. The company missed expectations in three of the last four quarters. The trailing four-quarter negative earnings surprise is 15.82%, on average.
In the last reported quarter, Innoviva delivered a negative earnings surprise of 10.0%.
Let’s see how things are shaping up prior to this announcement.
Factors at Play
Innoviva has a long-acting beta2 agonist (“LABA”) collaboration agreement with British pharma giant, Glaxo (GSK - Free Report) , which is the sole revenue source for the former. Under this agreement, Innoviva records royalties on global sales of certain Glaxo’s Ellipta products — Relvar/Breo, Anoro and Trelegy. Demand for these respiratory drugs is likely to have driven revenues for the company.
Trelegy Ellipta, the most recent among these, has demonstrated a strong growth trend in the first nine months of 2019. We expect strong demand for the drug to have continued in the fourth quarter, driving sales.
Moreover, U.S. sales of Anoro Ellipta returned to growth and ex-U.S. sales were strong in the third quarter. The sales-growth trend is likely to have continued in the soon-to-be reported quarter.
However, the U.S. generic launch of Glaxo’s respiratory drug, Advair, in early 2019 negatively impacted pricing for Relvar/Breo Ellipta in the United States. We expect U.S. sales to have declined in the quarter. Meanwhile, share gains in certain European markets and growth in Japan are likely to have driven sales in ex-U.S. markets for Relvar/Breo Ellipta.
We expect foreign currency translation to have positively impacted ex-U.S. sales of these drugs, thus driving royalties for Innoviva.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Innoviva this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Earnings ESP: Innoviva’s Earnings ESP is 0.00%. This is because both the Most Accurate Estimate and the Zacks Consensus Estimate stand at earnings of 60 cents.
Zacks Rank: Innoviva currently carries a Zacks Rank #3.
Innoviva, Inc. Price
Innoviva, Inc. price | Innoviva, Inc. Quote
Stocks That Warrant a Look
Here are some biotech stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat in their upcoming releases.
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) has an Earnings ESP of +5.39% and a Zacks Rank #3. The company is scheduled to release fourth-quarter results on Feb 6. You can see the complete list of today’s Zacks #1 Rank stocks here.
Horizon Pharma has an Earnings ESP of +1.85% and a Zacks Rank #3.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.7% per year. So be sure to give these hand-picked 7 your immediate attention.
See 7 handpicked stocks now >>